Geoffrey Glass

Kiniciti is a platform company that invests in and partners with companies to strengthen the cell and gene therapy ecosystem. The company, which is based in New York, NY, was founded by Geoffrey Michael Glass, who has been the CEO since incorporation. Kiniciti is backed by private equity firm Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners. The company offers a highly tailored, collaborative, and flexible investment and strategic support model to ensure the promise of cell and gene therapeutics is delivered quickly and safely to patients worldwide. The leadership team includes professionals experienced in investing in and building successful companies across the life sciences sector.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

Kiniciti is a platform company that invests in and partners with companies to strengthen the cell and gene therapy ecosystem. The company, which is based in New York, NY, was founded by Geoffrey Michael Glass, who has been the CEO since incorporation. Kiniciti is backed by private equity firm Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners. The company offers a highly tailored, collaborative, and flexible investment and strategic support model to ensure the promise of cell and gene therapeutics is delivered quickly and safely to patients worldwide. The leadership team includes professionals experienced in investing in and building successful companies across the life sciences sector.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

Kiniciti is a platform company that invests in and partners with companies to strengthen the cell and gene therapy ecosystem. The company, which is based in New York, NY, was founded by Geoffrey Michael Glass, who has been the CEO since incorporation. Kiniciti is backed by private equity firm Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners. The company offers a highly tailored, collaborative, and flexible investment and strategic support model to ensure the promise of cell and gene therapeutics is delivered quickly and safely to patients worldwide. The leadership team includes professionals experienced in investing in and building successful companies across the life sciences sector.

Kiniciti is a platform company that invests in and partners with companies to strengthen the cell and gene therapy ecosystem. The company, which is based in New York, NY, was founded by Geoffrey Michael Glass, who has been the CEO since incorporation. Kiniciti is backed by private equity firm Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners. The company offers a highly tailored, collaborative, and flexible investment and strategic support model to ensure the promise of cell and gene therapeutics is delivered quickly and safely to patients worldwide. The leadership team includes professionals experienced in investing in and building successful companies across the life sciences sector.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

Kiniciti is a platform company that invests in and partners with companies to strengthen the cell and gene therapy ecosystem. The company, which is based in New York, NY, was founded by Geoffrey Michael Glass, who has been the CEO since incorporation. Kiniciti is backed by private equity firm Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners. The company offers a highly tailored, collaborative, and flexible investment and strategic support model to ensure the promise of cell and gene therapeutics is delivered quickly and safely to patients worldwide. The leadership team includes professionals experienced in investing in and building successful companies across the life sciences sector.